

## JOINT COMMITTEE ON VACCINATION AND IMMUNISATION

### Minute of the meeting on 4 June 2014

#### Pneumococcal Vaccination Programme:

- PCV13 should remain the pneumococcal conjugate vaccine of choice for the UK at this time for the infant programme.
- Vaccine effectiveness for PCV13 is high and coverage of PCV vaccines is very good in the UK.
- A clear direct and indirect impact of PCV13 infant vaccination on each of the 13 vaccine serotypes observed
- Serotype 3 disease had still significantly reduced, despite earlier doubt about the vaccine's impact against this strain
- The full impact of the vaccine on invasive disease associated with PCV13 vaccine serotypes was unlikely to be seen for several more years
- Data provided by GSK on the impact of PCV10 on acute otitis media was not of sufficient weight to allow the Committee to advise any change from the current highly effective programme. Additionally, after reviewing the data on cross-protection provided by PCV10 against non-vaccine serotypes, the Committee expressed concerns that a shift from PCV13 to PCV10 could still have a negative impact on control of invasive pneumococcal disease in those serotypes contained in PCV13 but not in PCV10.
- A large effect of PCV13 on serotype 19A disease not seen with PCV10
- Modelling of impact and cost effectiveness of PPV will be undertaken and reviewed by the pneumococcal sub-committee.

#### Men B programme:

A DoH commissioned carriage study to evaluate impact of Bexsero on carriage is planned for 2015/16. The Committee reiterated its view that the carriage study remained an important study, as it could answer critical questions, highlighted by the cost-effectiveness modelling, regarding the efficacy of the Bexsero® meningococcal vaccine against acquisition of meningococcal carriage to inform assumptions of herd protection, and the committee expressed concern that the study would not begin earlier than 2015/16.